OZENOXACIN (T-3912)

Description: Ozenoxacin (formerly known as GF-001001-00; M-5120; T-3912; trade name: Xepi) is a novel nonfluorinated topical quinolone class of antibiotic. In December 2017, Ozenoxacin wa approved by FDA to treat impetigo. Ozenoxacin is active against some bacteria that have developed resistance to currently used quinolone and fluoroquinolone antibiotics. Compared with the activities of other quinolones against well-characterized quinolone-susceptible and quinolone-resistant Gram-positive bacteria, ozenoxacin was 3-fold to 321-fold more active than other quinolones. Ozenoxacin could represent a first-in-class nonfluorinated quinolone for the topical treatment of a broad range of dermatological infections.

References: Antimicrob Agents Chemother. 2013 Dec; 57(12):6389-92; J Antimicrob Chemother. 2015 Jan; 70(1):57-61.